Cargando…

Use of intravenous valproate in acute manic: about a clinical case

INTRODUCTION: Acute mania can have behavioral effects such as agitation, being a frequent cause of presentation in the emergency department. Pharmacological treatments include mood stabilizers and atypical antipsychotics. Valproate is an effective drug. However, the intravenous formulation is relega...

Descripción completa

Detalles Bibliográficos
Autores principales: Suárez Gómez, M., Suárez Gómez, A., Rodrigues, P., Sánchez Rus, S.S., Matos-Pires, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567726/
http://dx.doi.org/10.1192/j.eurpsy.2022.1042
_version_ 1784809472451936256
author Suárez Gómez, M.
Suárez Gómez, A.
Rodrigues, P.
Sánchez Rus, S.S.
Matos-Pires, A.
author_facet Suárez Gómez, M.
Suárez Gómez, A.
Rodrigues, P.
Sánchez Rus, S.S.
Matos-Pires, A.
author_sort Suárez Gómez, M.
collection PubMed
description INTRODUCTION: Acute mania can have behavioral effects such as agitation, being a frequent cause of presentation in the emergency department. Pharmacological treatments include mood stabilizers and atypical antipsychotics. Valproate is an effective drug. However, the intravenous formulation is relegated to other pathologies, such as epilepsy. OBJECTIVES: The objective was to review the use of intravenous valproate in acute mania in the literature and present its use through a clinical case. METHODS: A clinical case using intravenous valproate to treat an episode of acute mania is described and the scientific literature of the last 5 years is reviewed. RESULTS: A 43-year-old patient attended the emergency department with a diagnosis of bipolar disorder type I in manic episode with agitation, rejection of oral medication, brought in by the police due to risk of aggression against family members, who reported that the patient had stopped taking her usual medication with valproate 500 mg / 24h and quetiapine 200 mg / 24h threemonths ago. Due to the possibility of having intravenous valproate, it was decided to administer 300 mg intravenously, as well as haloperidol 5 mg intravenously, and hospitalization was decided. The patient had a favorable evolution, with no side effects to the medication, and oral treatment was started after 8 hours, with a good response. In the literature there are few studies in this regard, although the most of them approved the use of valproate as a loading dose in acute mania. CONCLUSIONS: Intravenous valproate is an effective, safe, and tolerated treatment in acute mania. More studies are needed to collect precise information. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9567726
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95677262022-10-17 Use of intravenous valproate in acute manic: about a clinical case Suárez Gómez, M. Suárez Gómez, A. Rodrigues, P. Sánchez Rus, S.S. Matos-Pires, A. Eur Psychiatry Abstract INTRODUCTION: Acute mania can have behavioral effects such as agitation, being a frequent cause of presentation in the emergency department. Pharmacological treatments include mood stabilizers and atypical antipsychotics. Valproate is an effective drug. However, the intravenous formulation is relegated to other pathologies, such as epilepsy. OBJECTIVES: The objective was to review the use of intravenous valproate in acute mania in the literature and present its use through a clinical case. METHODS: A clinical case using intravenous valproate to treat an episode of acute mania is described and the scientific literature of the last 5 years is reviewed. RESULTS: A 43-year-old patient attended the emergency department with a diagnosis of bipolar disorder type I in manic episode with agitation, rejection of oral medication, brought in by the police due to risk of aggression against family members, who reported that the patient had stopped taking her usual medication with valproate 500 mg / 24h and quetiapine 200 mg / 24h threemonths ago. Due to the possibility of having intravenous valproate, it was decided to administer 300 mg intravenously, as well as haloperidol 5 mg intravenously, and hospitalization was decided. The patient had a favorable evolution, with no side effects to the medication, and oral treatment was started after 8 hours, with a good response. In the literature there are few studies in this regard, although the most of them approved the use of valproate as a loading dose in acute mania. CONCLUSIONS: Intravenous valproate is an effective, safe, and tolerated treatment in acute mania. More studies are needed to collect precise information. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567726/ http://dx.doi.org/10.1192/j.eurpsy.2022.1042 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Suárez Gómez, M.
Suárez Gómez, A.
Rodrigues, P.
Sánchez Rus, S.S.
Matos-Pires, A.
Use of intravenous valproate in acute manic: about a clinical case
title Use of intravenous valproate in acute manic: about a clinical case
title_full Use of intravenous valproate in acute manic: about a clinical case
title_fullStr Use of intravenous valproate in acute manic: about a clinical case
title_full_unstemmed Use of intravenous valproate in acute manic: about a clinical case
title_short Use of intravenous valproate in acute manic: about a clinical case
title_sort use of intravenous valproate in acute manic: about a clinical case
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567726/
http://dx.doi.org/10.1192/j.eurpsy.2022.1042
work_keys_str_mv AT suarezgomezm useofintravenousvalproateinacutemanicaboutaclinicalcase
AT suarezgomeza useofintravenousvalproateinacutemanicaboutaclinicalcase
AT rodriguesp useofintravenousvalproateinacutemanicaboutaclinicalcase
AT sanchezrusss useofintravenousvalproateinacutemanicaboutaclinicalcase
AT matospiresa useofintravenousvalproateinacutemanicaboutaclinicalcase